154 related articles for article (PubMed ID: 35602496)
1. Blood HDAC4 Variation Links With Disease Activity and Response to Tumor Necrosis Factor Inhibitor and Regulates CD4+ T Cell Differentiation in Ankylosing Spondylitis.
Dou B; Ma F; Jiang Z; Zhao L
Front Med (Lausanne); 2022; 9():875341. PubMed ID: 35602496
[TBL] [Abstract][Full Text] [Related]
2. MALT1 positively relates to Th17 cells, inflammation/activity degree, and its decrement along with treatment reflects TNF inhibitor response in ankylosing spondylitis patients.
Yuan J; Xiang L; Wang F; Zhang L; Liu G; Chang X; Zhang A; Tao Y
J Clin Lab Anal; 2022 Jul; 36(7):e24472. PubMed ID: 35622982
[TBL] [Abstract][Full Text] [Related]
3. Serum PCSK9 is positively correlated with disease activity and Th17 cells, while its short-term decline during treatment reflects desirable outcomes in ankylosing spondylitis patients.
Cai J; Jiang Y; Chen F; Wu S; Ren H; Wang P; Wang J; Liu W
Ir J Med Sci; 2023 Aug; 192(4):1785-1791. PubMed ID: 36344709
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal variation of serum PCSK9 in ulcerative colitis: association with disease activity, T helper 1/2/17 cells, and clinical response of tumor necrosis factor inhibitor.
Deng J; Jiang Y; Luan L; Fu S; Huang M; Dai Z; Liao Y; Guo S; Fu Y
Ir J Med Sci; 2024 Feb; 193(1):165-172. PubMed ID: 37420045
[TBL] [Abstract][Full Text] [Related]
5. Serum HDAC4 level in rheumatoid arthritis: Longitudinal change during treatment and correlation with clinical outcomes.
Mou X; Jin Y; Jin D; Guan J; Zhang Q
J Clin Lab Anal; 2022 Aug; 36(8):e24594. PubMed ID: 35792020
[TBL] [Abstract][Full Text] [Related]
6. PBMC CDC42 reveals the disease activity and treatment efficacy of TNF inhibitor in patients with ankylosing spondylitis.
Zhang Q; Jin D; Mou X; Ye H
J Clin Lab Anal; 2022 Mar; 36(3):e24267. PubMed ID: 35104386
[TBL] [Abstract][Full Text] [Related]
7. Serum interα-trypsin inhibitor heavy chain H4 may be an anti-inflammatory marker reflecting disease risk, activity and treatment outcome of ankylosing spondylitis.
Sun Z; Zhang Y; Zhou H; Li J; Zhou Y; Wang L
Scand J Clin Lab Invest; 2023 Dec; 83(8):540-547. PubMed ID: 38156824
[TBL] [Abstract][Full Text] [Related]
8. JKAP serves as a potential biomarker for the evaluation of inflammatory condition, disease activity, and treatment response to TNF inhibitor in ankylosing spondylitis patients.
Zhou X; Li M
Mod Rheumatol; 2022 Apr; 32(3):613-618. PubMed ID: 34918117
[TBL] [Abstract][Full Text] [Related]
9. Blood MALT1, Th1, and Th17 cells are dysregulated, inter-correlated, and correlated with disease activity in rheumatoid arthritis patients; meanwhile, MALT1 decline during therapy relates to treatment outcome.
Ye Z; Chen L; Fang Y; Zhao L
J Clin Lab Anal; 2022 Jan; 36(1):e24112. PubMed ID: 34788483
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA intersectin 1-2 gradually declines during adalimumab treatment, and its reduction correlates with treatment efficacy in patients with ankylosing spondylitis.
Li M; Zhou X
Inflammopharmacology; 2021 Oct; 29(5):1371-1378. PubMed ID: 34406596
[TBL] [Abstract][Full Text] [Related]
11. TNF-α inhibitor therapy can improve the immune imbalance of CD4+ T cells and negative regulatory cells but not CD8+ T cells in ankylosing spondylitis.
Yang M; Lv Q; Wei Q; Jiang Y; Qi J; Xiao M; Fang L; Xie Y; Cao S; Lin Z; Zhang Y; Tu L; Zhao M; Pan Y; Jin O; Gu J
Arthritis Res Ther; 2020 Jun; 22(1):149. PubMed ID: 32560733
[TBL] [Abstract][Full Text] [Related]
12. Circulating levels of Th1 and Th2 chemokines in patients with ankylosing spondylitis.
Wang J; Zhao Q; Wang G; Yang C; Xu Y; Li Y; Yang P
Cytokine; 2016 May; 81():10-4. PubMed ID: 26827189
[TBL] [Abstract][Full Text] [Related]
13. In vivo peripheral blood proinflammatory T cells in patients with ankylosing spondylitis.
Limón-Camacho L; Vargas-Rojas MI; Vázquez-Mellado J; Casasola-Vargas J; Moctezuma JF; Burgos-Vargas R; Llorente L
J Rheumatol; 2012 Apr; 39(4):830-5. PubMed ID: 22337239
[TBL] [Abstract][Full Text] [Related]
14. Circulating HDAC4 reflects lipid profile, coronary stenosis and inflammation in coronary heart disease patients.
Guo Z; Wu Y; Feng Q; Wang C; Wang Z; Zhu Y; Lu X; Chen W; Yang Q; Huo Y
Biomark Med; 2023 Jan; 17(1):41-49. PubMed ID: 37013891
[TBL] [Abstract][Full Text] [Related]
15. Effects of 8-week kettlebell training on body composition, muscle strength, pulmonary function, and chronic low-grade inflammation in elderly women with sarcopenia.
Chen HT; Wu HJ; Chen YJ; Ho SY; Chung YC
Exp Gerontol; 2018 Oct; 112():112-118. PubMed ID: 30243898
[TBL] [Abstract][Full Text] [Related]
16. Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort.
Hebeisen M; Neuenschwander R; Scherer A; Exer P; Weber U; Tamborrini G; Micheroli R; Wildi LM; Zufferey P; Nissen MJ; Villiger PM; Bernhard J; Finckh A; van der Horst-Bruinsma IE; Sieper J; Landewé R; van der Heijde D; Ciurea A;
J Rheumatol; 2018 Apr; 45(4):506-512. PubMed ID: 29449504
[TBL] [Abstract][Full Text] [Related]
17. Th17, rather than Th1 cell proportion, is closely correlated with elevated disease severity, higher inflammation level, and worse prognosis in sepsis patients.
Liu Y; Wang X; Yu L
J Clin Lab Anal; 2021 May; 35(5):e23753. PubMed ID: 33704828
[TBL] [Abstract][Full Text] [Related]
18. Oral administration effects of β-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis.
Fattahi MJ; Ahmadi H; Jafarnezhad-Ansariha F; Mortazavi-Jahromi SS; Rehm BHA; Cuzzocrea S; Matsuo H; Mirshafiey A
Biomed Pharmacother; 2018 Apr; 100():495-500. PubMed ID: 29477913
[TBL] [Abstract][Full Text] [Related]
19. JNK Pathway-Associated Phosphatase Deficiency Facilitates Atherosclerotic Progression by Inducing T-Helper 1 and 17 Polarization and Inflammation in an ERK- and NF-κB Pathway-Dependent Manner.
Chen X; Fang M; Hong J; Guo Y
J Atheroscler Thromb; 2024 May; ():. PubMed ID: 38797677
[TBL] [Abstract][Full Text] [Related]
20. Clinical Significance of Peripheral Blood Th1 and Th17 Cell Content and Serum IL-35 and IL-17 Expression in Patients with Ankylosing Spondylitis.
Tan H; Huang S; Wang T
Evid Based Complement Alternat Med; 2022; 2022():6540557. PubMed ID: 35646154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
